Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 5, 2014, Pages 639-648

  Dong, Qian ^a   Zhang, Yao ^a   Yang, Xiang Hong ^a   Jing, Wei ^a   Zheng, Li Qiang ^a   Liu, Yun Peng ^a   Qu, Xiu Juan ^a   Li, Zhi ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PERINEURAL INVASION; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; TUMOR DIFFERENTIATION; TUMOR INVASION; BLOOD; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL RATE;

AGED; CALCIUM; CARCINOMA, PANCREATIC DUCTAL; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84912532438     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.01.012     Document Type: Article

References (52)

1. Berrino F., De Angelis R., Sant M., Rosso S., Bielska-Lasota M., Coebergh J.W., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-783.
2. Luo J., Xiao L., Wu C., Zheng Y., Zhao N. The incidence and survival rate of population-based pancreatic cancer patients:shanghai cancer registry 2004-2009. PLos One 2013, 8:e76052.
3. Pannala R., Basu A., Petersen G.M., Chari S.T. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009, 10:88-95.
4. Barugola G., Partelli S., Marcucci S., Sartori N., Capelli P., Bassi C., et al. Resectable pancreatic cancer: who really benefits from resection?. Ann Surg Oncol 2009, 16:3316-3322.
5. Tseng J.F., Raut C.P., Lee J.E., Pisters P.W., Vauthey J.N., Abdalla E.K., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004, 8:935-949.
6. Winter J.M., Cameron J.L., Campbell K.A., Arnold M.A., Chang D.C., Coleman J., et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006, 10:1199-1210.
7. David M., Lepage C., Jouve J.L., Jooste V., Chauvenet M., Faivre J., et al. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer 2009, 101:215-218.
8. Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003, 4:517-529.
9. Rizzuto R., Pozzan T. When calcium goes wrong: genetic alterations of a ubiquitous signaling route. Nat Genet 2003, 34:135-141.
10. Monteith G.R., Davis F.M., Roberts-Thomson S.J. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 2012, 287:31666-31673.
11. Monteith G.R., McAndrew D., Faddy H.M., Roberts-Thomson S.J. Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 2007, 7:519-530.
12. Liao J., Schneider A., Datta N.S., McCauley L.K. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006, 66:9065-9073.
13. Szendroi A., Speer G., Tabak A., Kosa J.P., Nyirady P., Majoros A., et al. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. Can J Urol 2011, 18:5710-5716.
14. Halthur C., Johansson A.L., Almquist M., Malm J., Grönberg H., Manjer J., et al. Serum calcium and the risk of prostate cancer. Cancer Causes Control 2009, 20:1205-1214.
15. Lehmann J., Retz M., Nürnberg N., Schnöckel U., Raffenberg U., Krams M., et al. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 2004, 101:1552-1562.
16. Shen H., Li Y., Liao Y., Zhang T., Liu Q., Du J. Lower blood calcium associates with unfavorable prognosis and predicts for bone metastasis in NSCLC. PLoS One 2012, 7:e34264.
17. Kobayashi N., Higurashi T., Iida H., Mawatari H., Endo H., Nozaki Y., et al. Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). J Hepatobiliary Pancreat Surg 2008, 15:531-535.
18. Kakizaki S., Ohya N., Yoshinaga T., Higuchi T., Kitazawa R., Takayama H., et al. Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy. Jpn J Clin Oncol 1998, 28:563-566.
19. Miraliakbari B.A., Asa S.L., Boudreau S.F. Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Hum Pathol 1992, 23:884-887.
20. Tachibana I., Nakano S., Akiyama T., Ogami Y., Tabaru A., Otsuki M. Parathyroid hormone-related protein mediates hypercalcemia in an exocrine pancreatic cancer. Am J Gastroenterol 1994, 89:1580-1581.
21. Yamamoto M., Nakano S., Mugikura M., Tachibana I., Ogami Y., Otsuki M. Pancreatic cancer and hypercalcemia associated with von Recklinghausen's disease. J Gastroenterol 1996, 31:728-731.
22. Edge S.B., Byrd D.R., Compton C.C. AJCC cancer staging manual 2010, Springer, New York.
23. Almquist M., Manjer J., Bondeson L., Bondeson A.G. Serum calcium and breast cancer risk: results from a prospective cohort study of 7847women. Cancer Causes Control 2007, 18:595-602.
24. Prins G.S., Korach K.S. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73:233-244.
25. Skinner H.G., Schwartz G.G. A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:575-578.
26. Skinner H.G., Schwartz G.G. Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2008, 17:2302-2305.
27. Mundy G.R., Guise T.A. Hormonal control of calcium homeostasis. Clin Chem 1999, 45:1347-1352.
28. Moseley J.M., Kubota M., Diefenbach-Jagger H., Wettenhall R.E., Kemp B.E., Suva L.J., et al. Parathyroid hormonerelated protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A 1987, 84:5048-5052.
29. Burtis W.J., Brady T.G., Orloff J.J., Ersbak J.B., Warrell R.P., Olson B.R., et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990, 322:1106-1112.
30. Strewler G.J., Stern P.H., Jacobs J.W., Eveloff J., Klein R.F., Leung S.C., et al. Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest 1987, 80:1803-1807.
31. Suva L.J., Winslow G.A., Wettenhall R.E., Hammonds R.G., Moseley J.M., Diefenbach-Jagger H., et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987, 237:893-896.
32. Abou-Samra A.B., Jüppner H., Force T., Freeman M.W., Kong X.F., Schipani E., et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci U S A 1992, 89:2732-2736.
33. Horiuchi N., Caulfield M.P., Fisher J.E., Goldman M.E., McKee R.L., Reagan J.E., et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 1987, 238:1566-1568.
34. Ralston S.H., Gallacher S.J., Patel U., Campbell J., Boyle I.T. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126treated patients. Ann Intern Med 1990, 112:499-504.
35. Yeung S.C., Eton O., Burton D.W., Deftos L.J., Vassilopoulou-Sellin R., Gagel R.F. Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma. Horm Res 1998, 49:288-291.
36. Bucht E., Rong H., Pernow Y., Nordqvist A.C., Eriksson E., Rankin W., et al. Parathyroid hormone-related protein in patients with primary breast cancer and eucalcemia. Cancer Res 1998, 58:4113-4116.
37. Ito M., Nakashima M., Alipov G.K., Matsuzaki S., Ohtsuru A., Yano H., et al. Gastric cancer associated with overexpression of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in relation to tumor progression. J Gastroenterol 1997, 32:396-400.
38. Bouvet M., Nardin S.R., Burton D.W., Behling C., Carethers J.M., Moossa A.R., et al. Human pancreatic adenocarcinomas express parathyroid hormone-related protein. J Clin Endocrinol Metab 2001, 86:310-316.
39. Bouvet M., Nardin S.R., Burton D.W., Lee N.C., Yang M., Wang X., et al. Parathyroid hormone-related protein as a novel tumor marker in pancreatic adenocarcinoma. Pancreas 2002, 24:284-290.
40. Holtrop M.E., Cox K.A., Clark M.B., Holick M.F., Anast C.S. 25-dihydroxycholecalciferol stimulates osteoclasts in rat bones in the absence of parathyroid hormone. Endocrinology 1981, 108:2293-2301.
41. Stolzenberg-Solomon R.Z., Jacobs E.J., Arslan A.A., Qi D., Patel A.V., Helzlsouer K.J., et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010, 172:81-93.
42. Wolpin B.M., Ng K., Bao Y., Kraft P., Stampfer M.J., Michaud D.S., et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2012, 21:82-91.
43. Zablotska L.B., Gong Z., Wang F., Holly E.A., Bracci P.M. Vitamin D, calcium, and retinol intake, and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control 2011, 22:91-100.
44. Bao Y., Ng K., Wolpin B.M., Michaud D.S., Giovannucci E., Fuchs C.S. Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer 2010, 102:1422-1427.
45. Chu C.K., Mazo A.E., Goodman M., Egnatashvili V., Sarmiento J.M., Staley C.A., et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 2010, 17:502-513.
46. Morrison M. Pancreatic cancer and diabetes. Adv Exp Med Biol 2012, 771:229-239.
47. Sahin I.H., Shama M.A., Tanaka M., Abbruzzese J.L., Curley S.A., Hassan M., et al. Association of diabetes and perineural invasion in pancreatic cancer. Cancer Med 2012, 1:357-362.
48. Ferrone C.R., Finkelstein D.M., Thayer S.P., Muzikansky A., Fernandez-delCastillo C., Warshaw A.L. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006, 24:2897-2902.
49. Kinsella T.J., Seo Y., Willis J., Stellato T.A., Siegel C.T., Harpp D., et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 2008, 31:446-453.
50. Chang D.K., Johns A.L., Merrett N.D., Gill A.J., Colvin E.K., Scarlett C.J., et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009, 27:2855-2862.
51. Kim J., Reber H.A., Dry S.M., Elashoff D., Chen S.L., Umetani N., et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 2006, 55:1598-1605.
52. Waraya M., Yamashita K., Katagiri H., Ishii K., Takahashi Y., Furuta K., et al. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 2009, 16:1231-1240.